Cargando…
COVID‐19 and plasma cells: Is there long‐lived protection?
Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long‐lived plasma cells (LLPC) are the mainstay...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350162/ https://www.ncbi.nlm.nih.gov/pubmed/35801537 http://dx.doi.org/10.1111/imr.13115 |
_version_ | 1784762187290509312 |
---|---|
author | Nguyen, Doan C. Lamothe, Pedro A. Woodruff, Matthew C. Saini, Ankur S. Faliti, Caterina E. Sanz, Ignacio Lee, Frances Eun‐Hyung |
author_facet | Nguyen, Doan C. Lamothe, Pedro A. Woodruff, Matthew C. Saini, Ankur S. Faliti, Caterina E. Sanz, Ignacio Lee, Frances Eun‐Hyung |
author_sort | Nguyen, Doan C. |
collection | PubMed |
description | Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long‐lived plasma cells (LLPC) are the mainstay of most effective vaccines. However, ending the pandemic has been hampered by the lack of long‐lived immunity after infection or vaccination. Although immunizations offer protection from severe disease and hospitalization, breakthrough infections still occur, most likely due to new mutant viruses and the overall decline of neutralizing antibodies after 6 months. Here, we review the current knowledge of B cells, from extrafollicular to memory populations, with a focus on distinct plasma cell subsets, such as early‐minted blood antibody‐secreting cells and the bone marrow LLPC, and how these humoral compartments contribute to protection after SARS‐CoV‐2 infection and immunization. |
format | Online Article Text |
id | pubmed-9350162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93501622022-08-04 COVID‐19 and plasma cells: Is there long‐lived protection? Nguyen, Doan C. Lamothe, Pedro A. Woodruff, Matthew C. Saini, Ankur S. Faliti, Caterina E. Sanz, Ignacio Lee, Frances Eun‐Hyung Immunol Rev Invited Reviews Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long‐lived plasma cells (LLPC) are the mainstay of most effective vaccines. However, ending the pandemic has been hampered by the lack of long‐lived immunity after infection or vaccination. Although immunizations offer protection from severe disease and hospitalization, breakthrough infections still occur, most likely due to new mutant viruses and the overall decline of neutralizing antibodies after 6 months. Here, we review the current knowledge of B cells, from extrafollicular to memory populations, with a focus on distinct plasma cell subsets, such as early‐minted blood antibody‐secreting cells and the bone marrow LLPC, and how these humoral compartments contribute to protection after SARS‐CoV‐2 infection and immunization. John Wiley and Sons Inc. 2022-07-08 2022-08 /pmc/articles/PMC9350162/ /pubmed/35801537 http://dx.doi.org/10.1111/imr.13115 Text en © 2022 The Authors. Immunological Reviews published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Invited Reviews Nguyen, Doan C. Lamothe, Pedro A. Woodruff, Matthew C. Saini, Ankur S. Faliti, Caterina E. Sanz, Ignacio Lee, Frances Eun‐Hyung COVID‐19 and plasma cells: Is there long‐lived protection? |
title |
COVID‐19 and plasma cells: Is there long‐lived protection?
|
title_full |
COVID‐19 and plasma cells: Is there long‐lived protection?
|
title_fullStr |
COVID‐19 and plasma cells: Is there long‐lived protection?
|
title_full_unstemmed |
COVID‐19 and plasma cells: Is there long‐lived protection?
|
title_short |
COVID‐19 and plasma cells: Is there long‐lived protection?
|
title_sort | covid‐19 and plasma cells: is there long‐lived protection? |
topic | Invited Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350162/ https://www.ncbi.nlm.nih.gov/pubmed/35801537 http://dx.doi.org/10.1111/imr.13115 |
work_keys_str_mv | AT nguyendoanc covid19andplasmacellsistherelonglivedprotection AT lamothepedroa covid19andplasmacellsistherelonglivedprotection AT woodruffmatthewc covid19andplasmacellsistherelonglivedprotection AT sainiankurs covid19andplasmacellsistherelonglivedprotection AT faliticaterinae covid19andplasmacellsistherelonglivedprotection AT sanzignacio covid19andplasmacellsistherelonglivedprotection AT leefranceseunhyung covid19andplasmacellsistherelonglivedprotection |